Pharmaceutical News

RSS

CRESTOR reduces major cardiovascular events in women by 46%

A new analysis of the JUPITER trial, released today at the American Heart Association meeting in Orlando, Florida, demonstrates that CRESTOR (rosuvastatin calcium) 20mg reduced first major cardiovascular events by 46%.

18 Nov 2009

Pediatric data for Pfizer's Lipitor submitted to the EMEA

Pfizer Inc announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission.

18 Nov 2009

Data demonstrate that danger of low levels of HDL is not reduced by statin treatment

Data released today at the American Heart Association (AHA) Scientific Sessions 2009 define the increased risk of heart attacks and cardiovascular disease in patients with low levels of HDL-C (known as "good cholesterol"). The data also determine that statins are unable to significantly impact the heart attack or cardiovascular disease risks associated with low HDL-C.

18 Nov 2009

Drug market for acute ischemic stroke to reach $450M in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of agents to treat acute ischemic stroke will remain relatively flat over the next decade, increasing from $360 million in 2008 to $450 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

18 Nov 2009

New study reveals certain prescription drugs can be harmful to fetus

More than six percent of expectant mothers in Quebec consume prescription drugs that are known to be harmful to their fetuses, according to a Universit- de Montr-al investigation published in the British Journal of Obstetrics and Gynaecology

18 Nov 2009

New Drug Application for NicOx's naproxcinod accepted for filing

NicOx S.A. today announced that it has received a filing communication from the U.S. Food and Drug Administration (FDA) stating that the New Drug Application (NDA) for naproxcinod is accepted for filing. NicOx submitted the NDA on September 24th, seeking approval for the relief of the signs and symptoms of osteoarthritis.

18 Nov 2009

On-going Phase 2b study conducted by Roche of ITMN-191 modified

InterMune, Inc. today announced that the on-going Phase 2b study conducted by Roche of ITMN-191 (RG7227) combined with standard of care (SOC) PEGASYS® (peginterferon alfa-2a) and COPEGUS® (ribavirin) in HCV treatment-naive patients has been modified.

18 Nov 2009

Pre-clinical data of GM1485 to be presented by GliaMed

GliaMed, Inc., a development stage biopharmaceutical company, today announced that Dr. David Weinstein, chief scientific officer and company founder, will present pre-clinical data demonstrating acceleration of wound healing through the in vivo induction and recruitment of stem cells at the Stem Cells USA & Regenerative Medicine Congress in Washington, D.C.

18 Nov 2009

Study examines link between folic acid and cancer incidence

Patients with heart disease in Norway, a country with no fortification of foods with folic acid, had an associated increased risk of cancer and death from any cause if they had received treatment with folic acid and vitamin B12, according to a study in the November 18 issue of JAMA.

18 Nov 2009

Study to test anti-tumor effects of AEOL 10150 initiated

Aeolus Pharmaceuticals, Inc. announced today the initiation of a study to test the anti-tumor effects of AEOL 10150 when combined with radiation and chemotherapy in nude mice bearing human non-small cell lung cancer (NSCLC) xenografts.

18 Nov 2009

Sildenafil improves heart function in youngsters with single ventricle congenital heart disease

Heart function significantly improved in children and young adults with single ventricle congenital heart disease who have had the Fontan operation following treatment with sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, say researchers from The Children's Hospital of Philadelphia.

18 Nov 2009

CTSA institutions receive NIH grants to study drug safety and efficacy in children

Studying drugs in pediatric populations is challenging because drugs often affect children differently than they do adults. The scarcity of pediatric studies limits the ability of doctors and scientists to predict drug dosing, safety and efficacy in children. To address this gap, the National Institutes of Health announced today 18 grants to help determine outcome measures and increase the likelihood of success of future trials of treatments for children.

18 Nov 2009

Tel Aviv University develops new wound dressing packed with infection-fighting antibiotics

Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections. But a revolutionary new wound dressing developed at Tel Aviv University could cut that number dramatically.

18 Nov 2009

Ongoing Phase 1 study results of XMT-1001 announced by Mersana Therapeutics

Mersana Therapeutics, a platform-based cancer therapeutics company, announced today additional preliminary results from an ongoing Phase 1 study of its lead development candidate, XMT-1001, in patients with advanced solid tumors.

18 Nov 2009

FDA approves Qutenza, a pain relief product for patients who suffer from PHN

The Food and Drug Administration (FDA) has approved the approval of Qutenza (capsaicin) 8% patch, a medicated skin patch that relieves the pain of post-herpetic neuralgia (PHN), a serious complication that can occur after a bout with shingles.

18 Nov 2009

SIRO Clinpharm and Mediscis team up to expand clinical development plans

SIRO Clinpharm, a global Contract Research Organization (CRO) with bases in India, US, Europe and Israel today announced their alliance with Mediscis, an early drug development company based in Poitiers and La Rochelle, France.

18 Nov 2009

China, WHO to collaborate on flu research center

Chinese and WHO officials last week agreed to open a flu research center in Beijing, Bloomberg reports. "The new collaborating center for reference and research on influenza will join a network of WHO-affiliated labs in Atlanta, London, Tokyo and Melbourne that monitor flu strains and make recommendations on vaccines to fight the virus," the news service writes

17 Nov 2009

Abbott and BG Medicine announce a development and commercialization agreement for galectin-3 biomarker

Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.

17 Nov 2009

Cancer pain drug market to be $3.7 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the continued dominance of opioids that include immediate-release morphine and novel fast acting opioid reformulations, the cancer pain drug market will increase from $2.3 billion in 2008 to $3.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

17 Nov 2009

Bavarian Nordic awarded a new contract for developing a freeze-dried version of its IMVAMUNE smallpox vaccine

Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.

17 Nov 2009